GLP-1 market heats up as companies vie for next-gen obesity drugs
2024年10月31日 · Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their …
Insilico’s lead drug meets safety and efficacy goals in IPF trial
2024年9月19日 · "These results are very encouraging, particularly the dose-dependent response in FVC. IPF is a devastating disease, and seeing improvements in lung function over just 12 …
Symbiosis unveils expanded facility at CPHI Milan 2024
2024年10月2日 · The event provides a great platform for the company to present its newest addition—a 20,000 sq ft facility in Stirling, UK, which the company says enhances Symbiosis' …
How will the Biosecure Act impact the pharma industry?
2024年10月8日 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first …
Merck acquires Modifi Biosciences in $1.3B cancer drug deal
2024年10月24日 · Modifi Biosciences, a spin out of Yale University founded in 2021, has been snapped up by Merck for $30 million paid upfront, and up to $1.3 billion in potential milestone …
GSK beefs up US manufacturing with $800 million
2024年10月29日 · “Marietta, PA, first emerged on the frontlines of vaccination production more than 140 years ago as the Lancaster County Vaccine Farm supplied the nation with life-saving …
NorthStar launches radiopharmaceutical CDMO
2024年10月24日 · The increasing integration of medical radioisotopes with diagnostic and molecular imaging as well as the rise of personalized medicine is spurring the growth of the …
FDA clearance to start clinical trials with new obesity drug
2024年10月10日 · The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
AbbVie set to file for FDA approval on tavapadon
2024年12月10日 · Dopamine receptors. By activating the dopamine receptors with dopamine agonists, some of the symptoms of Parkinson’s disease can be treated. Currently, D2/D3 …
Promising phase 2 results for Eli Lilly's Muvalaplin
2024年11月19日 · Yesterday, Eli Lilly and Company revealed promising Phase 2 results for its investigational small molecule drug, Muvalaplin, against cardiovascular events.